Shingrix Shingles Vaccine: FDA Wants GSK To Monitor Inflammation Risk
Executive Summary
GlaxoSmithKline's vaccine has 97.16% efficacy, surpassing Merck's Zostavax, but US advisory committee will weigh risks from inflammation which could cause ocular adverse effects and gout.
You may also be interested in...
GSK Shingles Vaccine's Next Stop Is CDC Panel After US FDA Approval
Shingrix's 90%-plus efficacy and reduction in postherpetic neuralgia gives GSK's vaccine edge over Merck's Zostavax. CDC advisory committee to vote on lower age for vaccination and use in Zostavax recipients.
GSK's Shingrix Shingles Vaccine Awaiting Final Labeling Tweaks
US advisory committee unanimously impressed by the 90% plus efficacy; FDA says label may note lack of data in those who've previously had shingles.
GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax
The strength of more detailed data on GSK’s shingles vaccine in older people from the Phase III ZOE-70 study raises prospects Shingrix can advance into a market that Merck’s Zostavax currently has to itself.